PRTK - Paratek Pharmaceuticals EPS beats by $0.08 beats on revenue

Paratek Pharmaceuticals (NASDAQ:PRTK): Q3 GAAP EPS of -$0.37 beats by $0.08. Revenue of $24.45M (+79.0% Y/Y) beats by $0.63M. Press Release Financial Guidance  Paratek anticipates net revenue of NUZYRA will be at the higher end of the previously indicated range of $100 to $106 million, which includes the $38 million NUZYRA procurement by BARDA in June 2021. Total Revenue is expected to be within the previously indicated range of $128 to $139 million.   Total R&D and SG&A expenses are projected to be within the original guidance range of $150 to $155 million. Based upon the company's current operating plan, Paratek anticipates its existing cash and cash equivalents of $111.0 million as of September 30, 2021, provides for a cash runway through the end of 2023 with a pathway to cash flow break even.

For further details see:

Paratek Pharmaceuticals EPS beats by $0.08, beats on revenue